#8 HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv--1*[tiab] OR hiv--2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno--deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-deficiency syndrome[tiab] OR acquired immune--deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp] #9 Antiretroviral Therapy, Highly Active[MeSH] OR Anti--Retroviral Agents[MeSH] OR Antiviral Agents[MeSH:NoExp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND (acquired immunodeficiency[tw])) OR ((anti) AND (acquired immuno--deficiency[tw])) OR ((anti) AND (acquired immune--deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw]))
re--suppress #19 resuppress #20 suppression #21 suppress #22 #17 OR #18 OR #19 OR #20 OR #21 #23 #7 AND #8 AND #9 AND #16 AND #22
Databases
The following databases will be searched from November 01 2012 (the date of the last review) to present:
• Medline via Pubmed • Embase In addition, all Conferences of the International AIDS Society and the Conference on Retroviruses and Opportunistic Infections will be searched from 2016 onwards to identify studies that have been completed but not yet published as full text.
Finally, major treatment providers (MSF, ICAP, I--TECH, etc) will be contacted in an attempt to obtain unpublished programmatic information.
Restrictions
No language, or geographical exclusions will be applied.
Types of studies
• Randomized--controlled trials • Prospective cohorts • Retrospecitve cohort • Programmatic data • Case series <20 patients will be included 2.
Types of participants Inclusions
• Adults and children with a high initial viral load and at least one subsequent viral load Exclusions
• Patients with only a single documented viral load 2.6. Types of outcomes The following outcomes will be reported:
• Number/proportion with second viral load suppressed • Number with clinical failure • Number with documented drug resistance following initial high viral load 3.0. Risk of bias Risk of bias will be assessed using appropriate tools for randomized trials and observational studies, adapted according to the final list of inclusions. The risk of bias items assessed were as follows:
Randomized trials
• Method of randomization described • Method of allocation concealment described • Reasons for discontinuation provided • No patient selection with respect to study inclusions • No patient selection with respect to outcome reporting
Observational studies
• Prospective vs retrospective study design • Adherence counseling documented • Outcomes described for all patients
• Enhanced adherence counseling documented for all patients • Drug resistance documented for all patients 4.0. Quantitative synthesis Descriptive statistics will be used to compare the number of studies published over time. Point estimates and 95% confidence intervals will be calculated for the proportion of individuals resuppressing following an initial high viral load. Data will be pooled using the DerSimonian--Laird random--effects method, 3 with proportions transformed prior to pooling using the Freeman-Tukey double arcsine transformation 4 and then back--transformed to the original scale. 5 We will calculated the τ 2 statistic using DerSimonian and Laird method of moments estimator to assess between--study heterogeneity. 6 Pre--planned subgroup analyses will be undertaken to determine the potential influence of the following covariates:
• Enhanced adherence counseling documented • VL threshold • Time to second VL • Background drug resistance (if available)
• Age • Advanced (CD4 <200) and very advanced (CD4 <100) HIV disease All P values will be reported as two--sides and P<.05 considered significant. All analyses were conducted using Stata version 14.0 (StataCorp, College Station, Tex).
